Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135389 | 1.00 | PSIP1 (0.48) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL7365625 | 0.81 | PSIP1 (0.52) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL7370842 | 0.79 | PSIP1 (0.48) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL6550974 | 0.77 | HSD11B1 (0.49) | PSIP1HSD11B1ALDH1A1TP53HTT | |
| SCHEMBL9426107 | 0.77 | PSIP1 (0.56) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL8910619 | 0.77 | PSIP1 (0.56) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL7724605 | 0.77 | PSIP1 (0.56) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL778303 | 0.77 | PSIP1 (0.60) | PSIP1POLBHSD11B1ALDH1A1TP53 | |
| SCHEMBL8414713 | 0.76 | POLB (0.47) | PSIP1POLBHSD11B1MEN1KMT2A | |
| SCHEMBL9218545 | 0.76 | POLB (0.47) | PSIP1POLBHSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1148347-C | Process for preparing hydroxy-25-ene-vitamin D compounds | ���ƹ��ʹ�˾ | 2004-05-05 | — | — | CN | claimed |
| EP-1091936-B1 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INT INC (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030009042-A1 | Method for making hydroxy-25-ene-vitamin D compounds | BONE CARE INTERNATIONAL, INC. | 2003-01-09 | — | — | US | claimed |
| US-6441207-B1 | REACTING 2,3-DIMETHYL-3-BUTENE PHENYL SULFONE WITH HYDROXYL PROTECTED C-22 ALDEHYDE OF A VITAMIN D; REDUCING, ISOMERIZ-ING AND DEPROTECTING; LOWER TOXICITY; ANTIPROLIFERATIVE AND DIFFERENTIATING EFFECTS; LESS CALCEMIC ACTIVITY | BONE CARE INTERNATIONAL, INC. | 2002-08-27 | — | — | US | claimed |
| CN-1303369-A | Process for preparing hydroxy-25-ene-vitamin D compounds | BONE CARE INT INC (US) | 2001-07-11 | — | — | CN | claimed |
| EP-1091936-A2 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INTERNATIONAL, INC. (US) | 2001-04-18 | — | — | EP | claimed |
| WO-1999061417-A2 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INTERNATIONAL, INC. (US) | 1999-12-02 | — | — | WO | claimed |
| CN-1148347-C | Process for preparing hydroxy-25-ene-vitamin D compounds | ���ƹ��ʹ�˾ | 2004-05-05 | — | — | CN | disclosed |
| EP-1091936-B1 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INT INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030009042-A1 | Method for making hydroxy-25-ene-vitamin D compounds | BONE CARE INTERNATIONAL, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6441207-B1 | REACTING 2,3-DIMETHYL-3-BUTENE PHENYL SULFONE WITH HYDROXYL PROTECTED C-22 ALDEHYDE OF A VITAMIN D; REDUCING, ISOMERIZ-ING AND DEPROTECTING; LOWER TOXICITY; ANTIPROLIFERATIVE AND DIFFERENTIATING EFFECTS; LESS CALCEMIC ACTIVITY | BONE CARE INTERNATIONAL, INC. | 2002-08-27 | — | — | US | disclosed |
| CN-1303369-A | Process for preparing hydroxy-25-ene-vitamin D compounds | BONE CARE INT INC (US) | 2001-07-11 | — | — | CN | disclosed |
| EP-1091936-A2 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INTERNATIONAL, INC. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-1999061417-A2 | METHOD FOR MAKING HYDROXY-25-ENE-VITAMIN D COMPOUNDS | BONE CARE INTERNATIONAL, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009042-A1 | Method for making hydroxy-25-ene-vitamin D compounds | CYP2R1, CYP24A1, VDR | PSIP1 4001/4885POLB 2984/4885HSD11B1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.